Predicting who may benefit from adjuvant immunotherapy in stage IIB melanoma - 11/08/25
Abstract |
Introduction |
Adjuvant immunotherapy is approved for patients with Stage IIB melanoma but carries risks and costs. The aim of this study was to identify high-risk stage IIB patients to help inform adjuvant immunotherapy decisions.
Methods |
The NCDB was queried to identify patients with stage IIB melanoma. Cox proportional hazards models identified risk factors for overall survival (OS). Conditional inference survival trees were used to create distinct risk groups. These groups were validated for melanoma-specific survival using SEER database.
Results |
12,610 patients were identified in the NCDB with Stage IIB melanoma. Three groups were identified with significant differences in OS: age <54, age ≥54 with MR ≤ 3/mm2, and age ≥54 with MR > 3/mm2. Among the 7599 patients with Stage IIB melanoma in the SEER database, the cumulative incidence of melanoma-specific death at 5 years was significantly different between these groups (12 % vs 15 % vs 20 %).
Conclusions |
Distinct melanoma-specific survival can be identified in stage IIB melanoma patients based on age and mitotic rate. These groups can be considered to inform decision-making for adjuvant therapy.
Le texte complet de cet article est disponible en PDF.Highlights |
• | Stage IIB melanoma carries a risk of distant metastatic recurrence, for which adjuvant immunotherapy is recommended. |
• | Immunotherapy has significant toxicities of immune mediated adverse events. |
• | Age >54 and mitotic rate >3 correlated with worse overall survival in patients with Stage IIB melanoma in the NCDB database. |
• | With these criteria applied to SEER database, there was a small but significant difference in melanoma-specific survival. |
• | Work is needed to determine tumor genetics or biologic markers predictive of immunotherapy benefit in stage IIB melanoma |
Keywords : Melanoma, Adjuvant, Immunotherapy, Survival
Plan
| This article is part of a special issue entitled: SWSC 2024 published in The American Journal of Surgery. |
Vol 247
Article 116450- septembre 2025 Retour au numéro
Article précédent
- Medicaid expansion and thyroid cancer stage at presentation: A comparative study of two US states
- Oluwasegun Akinyemi, Terhas Weldeslase, Mojisola Fasokun, Oluebubechukwu Eze, Eunice Odusanya, Austin Yap, Kelsey Limage, Kakra Hughes, Edward Cornwell, Adedoyin Kalejaiye
- Modification of splenorenal shunt using adrenal vein as a Conduit: Proximal spleno-adrenorenal shunt
- Anil K. Agarwal, Maktum Naik, Vageesh BG, Vaibhav Varshney, Sudheer K, Amit Javed, M.N. Saravanan
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?